Eli Lilly announces new Phase 2 data for orforglipron

Eli Lilly announced new Phase 2 data for orforglipron, its first nonpeptide oral glucagon-like peptide-1 receptor agonist being studied for chronic weight management in participants with obesity or overweighti. The results were shared during an oral presentation at the American Diabetes Association’s 83rd Scientific Sessions and were simultaneously published in the New England Journal of Medicine. Orforglipron met both primary and secondary endpoints for the efficacy estimandii and demonstrated clinically significant weight reductions in adults with obesity or overweight, with at least one weight-related comorbidity. At the 26-week primary endpoint, orforglipron showed statistically significant dose-dependent body weight reductions for all doses ranging from 8.6% to 12.6% compared to 2.0% for placebo. For those taking orforglipron, body weight continued to decrease at 36 weeks where all doses achieved body weight reductions ranging from 9.4% to 14.7% compared to 2.3% for placebo. The mean baseline body weight of participants was 240 lb. The safety profile of orforglipron was similar to other incretin-based therapies. Gastrointestinal side effects were the most commonly reported adverse events, were generally mild-to-moderate in severity, and usually occurred during the dose escalation period. Lilly has initiated Phase 3 development programs to further study the efficacy and safety of orforglipron for the treatment of obesity and overweight and type 2 diabetes.